Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Simvastatin therapy in cyclosporine A-induced alveolar bone loss in rats

Full text
Author(s):
Nassar, P. O. [1] ; Nassar, C. A. [2] ; Guimaraes, M. R. [1] ; Aquino, S. G. [1] ; Andia, D. C. [1] ; Muscara, M. N. [3] ; Spolidorio, D. M. P. [1] ; Rossa, Jr., C. [1] ; Spolidorio, L. C. [4]
Total Authors: 9
Affiliation:
[1] State Univ Sao Paulo, Dent Sch Araraquara, Dept Periodontol, Araraquara, SP - Brazil
[2] Univ State W Parana Unioeste, Cascavel Dent Sch, Dept Periodontol, Cascavel, Parana - Brazil
[3] Univ Sao Paulo USP, Inst Biomed Sci, Dept Pharmacol, Sao Paulo - Brazil
[4] State Univ Sao Paulo UNESP, Dent Sch Araraquara, Dept Physiol & Pathol, Araraquara, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: JOURNAL OF PERIODONTAL RESEARCH; v. 44, n. 4, p. 479-488, AUG 2009.
Web of Science Citations: 25
Abstract

Background and Objective: Cyclosporine A treatment is important in the therapy of a number of medical conditions; however, alveolar bone loss is an important negative side-effect of this drug. As such, we evaluated whether concomitant administration of simvastatin would minimize cyclosporine A-associated alveolar bone loss in rats subjected, or not, to experimental periodontal disease. Material and Methods: Groups of 10 rats each were treated with cyclosporine A (10 mg/kg/day), simvastatin (20 mg/kg/day), cyclosporine A and simvastatin concurrently (cyclosporine A/simvastatin) or vehicle for 30 days. Four other groups of 10 rats each received a cotton ligature around the lower first molar and were treated similarly with cyclosporine A, simvastatin, cyclosporine A/simvastatin or vehicle. Calcium (Ca(2+)), phosphorus and alkaline phosphatase levels were evaluated in serum. Expression levels of interleukin-1 beta, prostaglandin E(2) and inducible nitric oxide synthase were evaluated in the gingivomucosal tissues. Bone volume and numbers of osteoblasts and osteoclasts were also analyzed. Results: Treatment with cyclosporine A in rats, with or without ligature, was associated with bone loss, represented by a lower bone volume and an increase in the number of osteoclasts. Treatment with cyclosporine A was associated with bone resorption, whereas simvastatin treatment improved cyclosporine A-associated alveolar bone loss in all parameters studied. In addition, simvastatin, in the presence of inflammation, can act as an anti-inflammatory agent. Conclusion: This study shows that simvastatin therapy leads to a reversal of the cyclosporine A-induced bone loss, which may be mediated by downregulation of interleukin-1 beta and prostaglandin E(2) production. (AU)